IL312176A - Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis - Google Patents

Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Info

Publication number
IL312176A
IL312176A IL312176A IL31217624A IL312176A IL 312176 A IL312176 A IL 312176A IL 312176 A IL312176 A IL 312176A IL 31217624 A IL31217624 A IL 31217624A IL 312176 A IL312176 A IL 312176A
Authority
IL
Israel
Prior art keywords
prevention
treatment
oral preparation
intestinal fibrosis
pyridinone derivative
Prior art date
Application number
IL312176A
Other languages
English (en)
Hebrew (he)
Inventor
Roland Greinwald
Bernhard Tewes
Rudolf Wilhelm
Original Assignee
Dr Falk Pharma Gmbh
Roland Greinwald
Bernhard Tewes
Rudolf Wilhelm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Falk Pharma Gmbh, Roland Greinwald, Bernhard Tewes, Rudolf Wilhelm filed Critical Dr Falk Pharma Gmbh
Publication of IL312176A publication Critical patent/IL312176A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL312176A 2021-10-25 2022-10-24 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis IL312176A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2021/079584 WO2023072368A1 (en) 2021-10-25 2021-10-25 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
PCT/EP2022/079666 WO2023072878A1 (en) 2021-10-25 2022-10-24 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Publications (1)

Publication Number Publication Date
IL312176A true IL312176A (en) 2024-06-01

Family

ID=78536154

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312176A IL312176A (en) 2021-10-25 2022-10-24 Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis

Country Status (11)

Country Link
US (1) US20250041228A1 (cg-RX-API-DMAC10.html)
EP (1) EP4312994A1 (cg-RX-API-DMAC10.html)
JP (1) JP2024536609A (cg-RX-API-DMAC10.html)
KR (1) KR20240093898A (cg-RX-API-DMAC10.html)
CN (1) CN118234489A (cg-RX-API-DMAC10.html)
AU (1) AU2022374695A1 (cg-RX-API-DMAC10.html)
CA (1) CA3230682A1 (cg-RX-API-DMAC10.html)
IL (1) IL312176A (cg-RX-API-DMAC10.html)
MX (1) MX2024005076A (cg-RX-API-DMAC10.html)
WO (2) WO2023072368A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA202402786B (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297020A (en) 2020-04-24 2022-12-01 Dr Falk Pharma Gmbh A systemic preparation of a pyridonone derivative related to tg2
HRP20231072T1 (hr) 2020-04-24 2023-12-22 Dr. Falk Pharma Gmbh Sustavna formulacija derivata piridinona za celijakiju
WO2025153465A1 (en) * 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006052755A1 (de) * 2006-11-08 2008-05-15 N-Zyme Biotec Gmbh Michaelsysteme als Transglutaminaseinhibitoren
EP2687511A1 (de) * 2012-07-17 2014-01-22 Zedira GmbH Pyridinonderivate als Gewebetransglutaminaseinhibitoren

Also Published As

Publication number Publication date
JP2024536609A (ja) 2024-10-04
KR20240093898A (ko) 2024-06-24
US20250041228A1 (en) 2025-02-06
WO2023072368A1 (en) 2023-05-04
WO2023072878A1 (en) 2023-05-04
CN118234489A (zh) 2024-06-21
EP4312994A1 (en) 2024-02-07
AU2022374695A1 (en) 2024-03-21
CA3230682A1 (en) 2023-05-04
ZA202402786B (en) 2025-07-30
MX2024005076A (es) 2024-05-13

Similar Documents

Publication Publication Date Title
NO345131B1 (no) Kapselformulering av pirfenidon og farmasøytisk akseptable eksipienter
IL304680A (en) Urolithin history and methods of using them
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
IL288882A (en) Mixture of plant extracts for use in the prevention and/or treatment of chronic inflammatory bowel diseases
IL260955A (en) A mini tablet for oral administration containing sacubitril and valsartan for the treatment of heart failure
IL320856A (en) Pharmaceutical combinations and their uses
NO20052796D0 (no) Indolylpyrazinonderivater anvendelige for behandling av hyper-proliferative forstyrrelser og sykdommer assosiert med angiogenese
EP4215208A4 (en) PHARMACEUTICAL COMBINATION AND USE THEREOF
IL311331A (en) Pharmaceutical composition and use thereof
KR102217525B9 (ko) 치주염 예방 또는 치료용 유산균 및 그의 용도
IL291388A (en) Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment or alleviation of cancer
DK4255563T3 (da) 5´-o-phenylacetyluridin og terapeutisk anvendelse
IL289289A (en) History of polyaromatic ureas and their use in the treatment of muscle diseases
PH12021550875A1 (en) 3-(1,2,3,6-tetrahydropyridin-2-yl)pyridine glutarate or a pharmaceutically acceptable solvate thereof
EP4380919A4 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
DK3842423T3 (da) 3-azabicyclo[3,1,1]heptanderivat og farmaceutisk sammensætning omfattende denne
IL299338A (en) Heterocyclic derivatives, pharmaceutical preparations and their use for the treatment, amelioration or prevention of fibrotic disease
IL312874A (en) Pharmaceutical composition and use thereof
IL307402A (en) The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
IL280550A (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
PL3983066T3 (pl) Leczenie niewydolności serca i zwłóknienia u ludzkich osobników
PL3937948T3 (pl) Fitoekdyzony i ich pochodne do ich zastosowania w leczeniu chorób nerwowo-mięśniowych
IL268131A (en) A pharmaceutical composition comprising an oxazine derivative and its use in the treatment or prevention of alzheimer's disease
HK40106888A (en) Oral formulation of a pyridinone derivate and use thereof in prophylaxis and/or treatment of intestinal fibrosis
IL285297A (en) Compositions and methods for the treatment of constipation and other ailments of the gastrointestinal system